What are the recommendations, safety profile, and efficacy of the RSV (respiratory syncytial virus) vaccine for pregnant individuals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

RSV Vaccine in Pregnancy

The CDC/ACIP recommends RSVpreF vaccine (Abrysvo) as a single dose at 32-36 weeks' gestation during September through January for pregnant individuals to prevent severe RSV disease in infants under 6 months of age. 1

Key Recommendation Details

The RSVpreF vaccine should be administered:

  • Timing: Between 32 weeks 0 days and 36 weeks 6 days of gestation
  • Seasonality: September through end of January in most of the continental United States
  • Dose: Single 0.5 mL intramuscular injection (one-time dose)
  • Formulation: Bivalent vaccine containing stabilized prefusion F glycoproteins from RSV A and RSV B 1

Efficacy Against Infant Disease

The vaccine demonstrates strong protection for infants:

  • 57.3% efficacy against medically attended RSV lower respiratory tract infection (LRTI) in infants 0-180 days old
  • 76.5% efficacy against severe medically attended RSV-LRTI
  • 48.2% efficacy against RSV-associated hospitalization 1

A recent meta-analysis of 6 trials involving over 18,000 pregnant women confirmed these benefits, showing the vaccine reduces severe RSV-LRTI (RR 0.35,95% CI 0.15-0.87) and RSV-related hospitalization (RR 0.53,95% CI 0.37-0.76) within 180 days of birth 2.

Safety Profile and Important Warnings

The FDA has labeled a warning for potential preterm birth risk, though clinical trial data showed no statistically significant difference between vaccine and placebo groups 1. Key safety considerations:

Maternal Safety:

  • Most common reactions: injection site pain (40.6%), headache (31.0%), muscle pain (26.5%), nausea (20.0%)
  • Non-statistically significant increases observed in preterm births and hypertensive disorders of pregnancy (including preeclampsia) compared to placebo
  • The FDA restricted use to 32-36 weeks specifically to avoid potential preterm birth risk before 32 weeks, which carries higher morbidity and mortality 1

Reassuring Long-term Data:

Recent observational studies show no increased adjusted odds ratios for preterm delivery, hypertensive disorders, cesarean section, low birth weight, or NICU admission compared to unvaccinated cohorts 3. The 2026 meta-analysis found no safety signal for preterm birth (RR 1.15,95% CI 0.95-1.38), low birth weight, or congenital malformations 2.

Critical Clinical Decision: Vaccine vs. Nirsevimab

Either maternal vaccination OR infant nirsevimab (monoclonal antibody) is recommended—but both are not needed for most infants 1. This is a crucial counseling point.

Choose Maternal RSVpreF Vaccine When:

  • Pregnant person is 32-36 weeks during September-January
  • Desire for immediate protection at birth
  • Preference to avoid infant injection
  • Concern about potential RSV F protein mutations (vaccine produces polyclonal response) 1

Choose Infant Nirsevimab When:

  • Mother has contraindication to vaccination
  • Infant born <34 weeks gestation (always give nirsevimab regardless of maternal vaccination)
  • Infant born <14 days after maternal vaccination (insufficient time for antibody transfer)
  • Mother's vaccination status unknown
  • Infant born outside RSV season (April-September) and entering first RSV season at <8 months
  • Immunocompromised mother (may have reduced antibody production/transfer) 1

Mechanism and Duration of Protection

Maternal antibodies:

  • Require at least 14 days after vaccination for adequate development and transplacental transfer 1
  • Transfer efficiently with ratios of 1.39-1.83 (cord blood to maternal blood) 4
  • Peak at delivery with geometric mean titer ratios 10.9-13.6 times higher than placebo 4
  • Protection likely wanes after 3 months, similar to influenza and COVID-19 maternal vaccines 1
  • Antibody half-life in infants: 39-44 days 4

Common Pitfalls to Avoid

  1. Do not vaccinate before 32 weeks due to preterm birth concerns, even if patient requests earlier vaccination
  2. Do not give both vaccine and nirsevimab to most infants—this wastes resources and provides no additional benefit
  3. Do not vaccinate outside September-January in most of the continental U.S., as infants won't be protected during peak RSV season
  4. Do not assume maternal vaccination protects preterm infants born <34 weeks—they need nirsevimab regardless
  5. Do not forget the 14-day rule—infants born <14 days post-vaccination need nirsevimab

Special Populations Requiring Nirsevimab Despite Maternal Vaccination

Nirsevimab may be considered for infants of vaccinated mothers in rare circumstances based on clinical judgment:

  • Immunocompromised mothers who may not mount adequate antibody response
  • Mothers who may not efficiently transfer antibodies
  • Infants at exceptionally high risk for severe RSV disease 1

Excluded Populations from Trials

Pregnant persons at increased risk for preterm delivery were excluded from phase 2b and 3 trials, limiting safety data in this high-risk group 1.

References

Related Questions

Should RSV vaccination be given to the pregnant mother in the third trimester, or should RSV prophylaxis (nirsevimab) be administered to the newborn at birth?
Can a pregnant woman at 35 weeks gestation receive a respiratory syncytial virus (RSV) vaccine today?
Can the inactivated influenza vaccine, RSV vaccine, and Tdap (tetanus‑diphtheria‑pertussis) vaccine be administered together during pregnancy?
If the mother is unsure whether she received the RSV vaccine during pregnancy, should a 2‑month‑old infant receive RSV prophylaxis (e.g., nirsevimab) and what are the consequences of an extra dose of palivizumab (Synagis)?
What is the premise of using RSV‑specific antibodies for passive immunization, and what are the recommended first‑line and emerging prophylactic options?
Why administer 10 mg of naloxone (Narcan) for opioid or drug‑induced cardiac or respiratory arrest?
What post‑void residual volume is considered significant in a 77‑year‑old male?
For a brain and spine MRI scheduled at [TIME], what is the optimal timing to take 2 mg of lorazepam (Ativan) to ensure it is effective during the scan?
Why is a total naloxone dose of up to 10 mg recommended for atypical or high‑potency opioids?
Is insertion of a cephalomedullary nail for a femur fracture considered open reduction internal fixation (ORIF)?
After initiating digoxin for rate control, how soon can amiodarone be started?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.